You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

E1784K mutation

Showing 1 - 25 of 3,633
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stratification of Overlap Syndrome Phenotype in E1784K Mutation

Recruiting
  • Long QT Syndrome
  • +3 more
    • Saint-Pierre, France, Réunion
      CHU de La Réunion
    Oct 19, 2022

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    Medium-chain Acyl-CoA Dehydrogenase Deficiency Trial in Pittsburgh (Sodium phenylbutyrate)

    Recruiting
    • Medium-chain Acyl-CoA Dehydrogenase Deficiency
    • Sodium phenylbutyrate
    • Pittsburgh, Pennsylvania
      UPMC Children's Hospital of Pittsburgh
    Oct 4, 2023

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

    Active, not recruiting
    • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)

    Recruiting
    • EGFR NP_005219.2:p.S492R
    • +7 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

    Completed
    • Metastatic Melanoma
    • Palliative radiotherapy
    • Dabrafenib and trametinib (combination)
    • Darlinghurst, New South Wales, Australia
    • +2 more
    Apr 6, 2022

    BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

    Recruiting
    • BRAF NP_004324.2:p.V600E
    • +2 more
    • Duarte, California
    • +1 more
    Jan 19, 2023

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

    Active, not recruiting
    • BRAF V600E Mutation Present
    • +9 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2022

    Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

    Recruiting
    • Melanoma
    • Siena, Toscana, Italy
    • +11 more
    Jun 23, 2023

    Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor Trial (drug, procedure, biological)

    Not yet recruiting
    • Advanced Malignant Solid Neoplasm
    • Locally Advanced Malignant Solid Neoplasm
    • (no location specified)
    Dec 2, 2022

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

    Terminated
    • BRAF V600E Mutation Present
    • +7 more
    • Boston, Massachusetts
    • +1 more
    Mar 9, 2022

    Locally Advanced or Metastatic Breast Cancer Trial in Canada, Israel, United States (Lasofoxifene, Fulvestrant)

    Active, not recruiting
    • Locally Advanced or Metastatic Breast Cancer
    • Phoenix, Arizona
    • +50 more
    Oct 24, 2022

    Parkinson's Disease Trial in Worldwide (venglustat GZ/SAR402671, Placebo)

    Terminated
    Has Results
    • Parkinson's Disease
    • venglustat GZ/SAR402671
    • Placebo
    • Scottsdale, Arizona
    • +51 more
    May 3, 2022

    NSCLC, Colorectal Cancer, Advanced Solid Tumors Trial in Worldwide (GDC-6036, Atezolizumab, Cetuximab)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Duarte, California
    • +68 more
    Jan 10, 2023

    Melanoma Trial in New York (Dabrafenib)

    Completed
    Has Results
    • Melanoma
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    May 8, 2020

    Advanced NSCLC, Metastatic NSCLC Trial in Worldwide (MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab)

    Recruiting
    • Advanced Non-Small Cell Lung Cancer
    • Metastatic Non-Small Cell Lung Cancer
    • MRTX849 Monotherapy
    • +2 more
    • Prescott Valley, Arizona
    • +134 more
    Jan 25, 2023

    Ovarian Cancer Trial in Chengdu (Yangzheng Xiaoji, Niraparib)

    Not yet recruiting
    • Ovarian Cancer
    • Chengdu, Sichuan, China
      Sicchuan cancer hospital
    Nov 30, 2022

    InheriteD brEast caNcer iTalian regIsTrY A

    Recruiting
    • Breast Cancer
      • Aviano, Pordenone, Italy
      • +11 more
      Apr 26, 2023

      Melanoma Trial in Worldwide (Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib)

      Recruiting
      • Melanoma
      • Encorafenib and Binimetinib
      • Placebo to match Encorafenib ; Placebo to match Binimetinib
      • Caba, Buenos Aires, Argentina
      • +169 more
      Jul 5, 2022

      Melanoma Trial in Worldwide (Atezolizumab, Atezolizumab Placebo, Cobimetinib)

      Active, not recruiting
      Has Results
      • Melanoma
      • Birmingham, Alabama
      • +115 more
      Jul 11, 2022

      Homologous Recombination Repair Pathway Gene Mutation Spectrum

      Not yet recruiting
      • Breast Cancer
        • (no location specified)
        Jun 4, 2023

        Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic Trial in Worldwide (Ataluren, PLACEBO)

        Active, not recruiting
        • Muscular Dystrophy, Duchenne
        • +8 more
        • Phoenix, Arizona
        • +71 more
        Mar 30, 2022

        Cancer Trial (Dabrafenib, Trametinib)

        Not yet recruiting
        • Cancer
        • (no location specified)
        May 25, 2023

        Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

        Active, not recruiting
        • Advanced Cholangiocarcinoma
        • FGFR2 Gene Mutation
        • Gilbert, Arizona
        • +115 more
        Oct 17, 2022

        Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)

        Recruiting
        • Creutzfeldt-Jakob Disease (CJD)
          • Tel Aviv, Israel
            Cognitive Neurology Unit
          Feb 27, 2023